Stock listing
NASDAQ:LSTA Lisata Therapeutics, Inc. Stock
Home listing (NASDAQ) of Lisata Therapeutics, Inc.
Follow Lisata Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LSTA
$0.899 USD -0.081 (-8.3%)
Close on Nov 20, 2026
- Day range
- $0.850 – $0.900 USDNov 20, 2026
- Volume
- 139,259 sharesNov 20, 2026
- Market cap
- $9.71M USDAt the close on Nov 20, 2026 · price × 10.80M shares outstanding
- 52-week range
- $0.850 – $5.070 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $460,210 USDMedian day 96,293 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LSTA · Home | $0.899 USD | -0.081 (-8.3%) | 139,259 | $0.883 | $0.900 | $0.850 | $0.980 | Close on Nov 20, 2026 |
| LSE:0HS8 | $0.925 USD | -0.061 (-6.2%) | 4,034 | $0.950 | $0.967 | $0.910 | $0.987 | Close on Nov 19, 2026 |
| Frankfurt:8NE | €0.70 EUR | -0.035 (-4.8%) | — | €0.70 | €0.70 | €0.70 | €0.735 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LSTA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.899 | -0.081 | -8.3% | $0.883 | $0.900 | $0.850 | 139,259 | |
| $0.980 | -0.060 | -5.8% | $1.050 | $1.105 | $0.892 | 222,092 | |
| $1.040 | -0.050 | -4.6% | $1.080 | $1.100 | $1.000 | 246,917 | |
| $1.090 | -0.120 | -9.9% | $1.160 | $1.220 | $1.040 | 44,987 | |
| $1.210 | -0.070 | -5.5% | $1.250 | $1.260 | $1.200 | 104,863 | |
| $1.280 | +0.080 | +6.7% | $1.210 | $1.300 | $1.150 | 119,688 | |
| $1.200 | +0.180 | +17.6% | $1.030 | $1.430 | $1.030 | 1,061,414 | |
| $1.020 | -0.100 | -8.9% | $1.090 | $1.090 | $1.010 | 20,347 | |
| $1.120 | +0.090 | +8.7% | $1.060 | $1.210 | $0.985 | 292,876 | |
| $1.030 | +0.038 | +3.9% | $1.020 | $1.060 | $0.990 | 15,114 | |
| $0.992 | -0.069 | -6.5% | $1.060 | $1.069 | $0.992 | 63,267 | |
| $1.060 | -0.030 | -2.8% | $1.063 | $1.105 | $1.060 | 13,622 | |
| $1.090 | +0.080 | +7.9% | $1.010 | $1.090 | $1.010 | 29,512 | |
| $1.010 | -0.010 | -1.0% | $1.080 | $1.148 | $1.000 | 97,147 | |
| $1.020 | +0.010 | +1.0% | $0.990 | $1.090 | $0.990 | 60,778 | |
| $1.010 | -0.050 | -4.7% | $1.040 | $1.120 | $0.990 | 27,843 | |
| $1.060 | +0.040 | +3.9% | $1.010 | $1.120 | $1.010 | 75,391 | |
| $1.020 | -0.040 | -3.8% | $1.040 | $1.040 | $1.010 | 40,773 | |
| $1.060 | +0.064 | +6.4% | $0.980 | $1.060 | $0.961 | 60,317 | |
| $0.996 | -0.009 | -0.9% | $1.000 | $1.010 | $0.970 | 45,557 | |
| $1.005 | -0.045 | -4.3% | $1.060 | $1.060 | $1.000 | 27,668 | |
| $1.050 | +0.010 | +1.0% | $1.050 | $1.070 | $1.010 | 45,570 | |
| $1.040 | +0.040 | +4.0% | $1.000 | $1.080 | $0.996 | 113,743 | |
| $1.000 | -0.030 | -2.9% | $1.030 | $1.040 | $0.960 | 96,293 | |
| $1.030 | -0.040 | -3.7% | $1.040 | $1.070 | $1.020 | 57,126 | |
| $1.070 | +0.050 | +4.9% | $1.050 | $1.070 | $1.000 | 23,166 | |
| $1.020 | -0.060 | -5.6% | $1.000 | $1.070 | $0.996 | 80,257 | |
| $1.080 | +0.030 | +2.9% | $1.100 | $1.150 | $0.990 | 146,856 | |
| $1.050 | -0.010 | -0.9% | $1.040 | $1.060 | $0.980 | 166,669 | |
| $1.060 | -0.140 | -11.7% | $1.280 | $1.280 | $1.020 | 280,231 | |
| $1.200 | +0.030 | +2.6% | $1.220 | $1.310 | $1.130 | 704,822 | |
| $1.170 | -0.040 | -3.3% | $1.220 | $1.220 | $1.160 | 13,582 | |
| $1.210 | -0.050 | -4.0% | $1.310 | $1.320 | $1.140 | 124,181 | |
| $1.260 | -0.210 | -14.3% | $1.450 | $1.475 | $1.260 | 90,753 | |
| $1.470 | -0.020 | -1.3% | $1.490 | $1.500 | $1.470 | 3,681 | |
| $1.490 | +0.050 | +3.5% | $1.420 | $1.560 | $1.420 | 63,138 | |
| $1.440 | -0.030 | -2.0% | $1.470 | $1.500 | $1.435 | 17,080 | |
| $1.470 | -0.030 | -2.0% | $1.480 | $1.536 | $1.440 | 50,722 | |
| $1.500 | -0.080 | -5.1% | $1.560 | $1.570 | $1.500 | 38,184 | |
| $1.580 | +0.080 | +5.3% | $1.540 | $1.580 | $1.490 | 47,897 | |
| $1.500 | +0.065 | +4.5% | $1.470 | $1.530 | $1.435 | 25,475 | |
| $1.435 | -0.045 | -3.0% | $1.460 | $1.500 | $1.400 | 77,241 | |
| $1.480 | -0.080 | -5.1% | $1.550 | $1.600 | $1.440 | 152,755 | |
| $1.560 | -0.140 | -8.2% | $1.640 | $1.650 | $1.540 | 228,887 | |
| $1.700 | -0.040 | -2.3% | $1.710 | $1.760 | $1.610 | 293,908 | |
| $1.740 | +0.270 | +18.4% | $2.500 | $2.560 | $1.500 | 3,043,749 | |
| $1.470 | -0.070 | -4.5% | $1.530 | $1.570 | $1.470 | 93,541 | |
| $1.540 | -0.020 | -1.3% | $1.530 | $1.560 | $1.430 | 157,865 | |
| $1.560 | -0.070 | -4.3% | $1.680 | $1.680 | $1.455 | 169,191 | |
| $1.630 | -0.010 | -0.6% | $1.720 | $1.720 | $1.567 | 111,886 | |
| $1.640 | -0.260 | -13.7% | $1.915 | $1.915 | $1.538 | 236,640 | |
| $1.900 | +0.040 | +2.2% | $1.860 | $1.999 | $1.730 | 208,266 | |
| $1.860 | +0.210 | +12.7% | $1.650 | $1.890 | $1.620 | 252,498 | |
| $1.650 | +0.010 | +0.6% | $1.580 | $1.700 | $1.564 | 33,923 | |
| $1.640 | +0.070 | +4.5% | $1.570 | $1.710 | $1.450 | 162,868 | |
| $1.570 | 0.000 | 0.0% | $1.520 | $1.640 | $1.450 | 113,611 | |
| $1.570 | +0.080 | +5.4% | $1.480 | $1.640 | $1.234 | 475,598 | |
| $1.490 | -0.200 | -11.8% | $1.660 | $1.660 | $1.440 | 243,389 | |
| $1.690 | -0.130 | -7.1% | $1.800 | $1.815 | $1.540 | 245,048 | |
| $1.820 | +0.010 | +0.6% | $1.760 | $1.940 | $1.760 | 86,666 | |
| $1.810 | +0.070 | +4.0% | $1.760 | $1.870 | $1.750 | 51,731 | |
| $1.740 | -0.020 | -1.1% | $1.750 | $1.900 | $1.720 | 184,299 | |
| $1.760 | +0.210 | +13.5% | $1.630 | $2.000 | $1.600 | 1,094,249 | |
| $1.550 | +0.430 | +38.4% | $1.110 | $1.790 | $1.104 | 7,120,557 | |
| $1.120 | 0.000 | 0.0% | $1.130 | $1.165 | $1.070 | 94,818 |
Splits
5 splits since 2006 · NASDAQ:LSTA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:LSTA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
Latest deck · November 2026
Marea Therapeutics — Investor Presentation (November 2026)
Investor deck · 22 slides
Latest news
Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
Nov 19, 2026
Closed $0.899 (-8.3%) on Nov 20, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
Nov 9, 2026
Closed $1.12 (+8.7%) on Nov 9, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
Nov 5, 2026
Closed $0.992 (-6.5%) on Nov 5, 2026
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Oct 14, 2026
Closed $1.07 (+4.9%) on Oct 15, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Oct 5, 2026
Closed $1.26 (-14.3%) on Oct 5, 2026
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Sep 17, 2026
Closed $1.74 (+18.4%) on Sep 17, 2026
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Aug 4, 2026
Closed $1.14 (+9.6%) on Aug 4, 2026
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Jun 10, 2026
Closed $3.61 (+4.3%) on Jun 10, 2026
Kuva Intends to Commence Tender Offer for Lisata Therapeutics by May 29, 2026
May 4, 2026
Closed $3.35 (+7.0%) on May 4, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Mar 6, 2026
Closed $5.04 (+20.6%) on Mar 9, 2026
Lisata Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 36 in all · newest Nov 19, 2026 · oldest 2025
- Calls
- 13 calls with a replay · 13 with a transcript · latest Nov 6, 2025
- Decks
- 93 decks · latest November 2026
Where Lisata Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LSTA · Home listing · This page | NASDAQ | United States | USD |
| Lang & Schwarz:A3DWGC | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3DWGC | LS Exchange | Germany | EUR |
| Munich:8NE | Munich | Germany | EUR |
| gettex:8NE | gettex | Germany | EUR |
| LSE:0HS8 | LSE | United Kingdom | USD |
| BOATS:LSTA | BOATS | United States | USD |
| Dusseldorf:8NE | Dusseldorf | Germany | EUR |
| Frankfurt:8NE | Frankfurt | Germany | EUR |
| Stuttgart:8NE | Stuttgart | Germany | EUR |
| Tradegate:8NE | Tradegate | Germany | EUR |
Valuation
EV/sales −2,730× against a median of −5.9×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$273.0M USD
- P/E
- Loss
- EV/sales
- −2,730×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.71
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Alzinova AB · OMXSTO:ALZ | US$9.58M | US$8.35M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| Median of the others | US$9.58M | US$4.33M | 0.1× | −5.9× | 0.6× | −303.7% | 0.0× | 1.35 |
Forecasts
2 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.09 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| David J. Mazzo | President and Chief Executive Officer |
| Tariq Imam | Senior Vice President, Business Development and Operations and General Counsel |
| John Menditto | Vice President, Investor Relations and Corporate Communications |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer |
Board
| Director | Role |
|---|---|
| Gregory B. Brown | Chairman |
| Cynthia L. Flowers | Director |
| Heidi Henson | Director |
| Jeff Farrow | Director |
| Mohammad Azab | Director |
| Steven M. Klosk | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Lisata Therapeutics (NASDAQ:LSTA) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q2 2024 Earnings Call | Mon, Aug 12, 2024 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q4 2023 Earnings Call | Thu, Feb 29, 2024 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q3 2023 Earnings Call | Thu, Nov 02, 2023 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q2 2023 Earnings Call | Tue, Aug 15, 2023 · 8:30 AM ET | Replay |
All 13 calls
| Call | When | Status |
|---|---|---|
| Lisata Therapeutics (NASDAQ:LSTA) Q1 2023 Earnings Call | Tue, May 09, 2023 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q4 2022 Earnings Call | Thu, Mar 30, 2023 · 4:30 PM ET | Replay |
| Lisata Therapeutics (NASDAQ:LSTA) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −9.9% |
| Q2 2026 | Aug 20, 2026 | +38.4% |
| Q1 2026 | May 7, 2026 | −3.4% |
| Q4 2025 | Feb 26, 2026 | −6.6% |
| Q3 2025 | Nov 6, 2025 · After close | −12.3% |
| Q2 2025 | Aug 7, 2025 · After close | −7.1% |
| Q1 2025 | May 8, 2025 · After close | −11.6% |
| Q4 2024 | Feb 26, 2025 · After close | +0.4% |
| Q3 2024 | Nov 12, 2024 · After close | −4.1% |
| Q2 2024 | Aug 12, 2024 · After close | +0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +1.3% |
| Q4 2023 | Feb 29, 2024 · After close | +5.8% |
| Q3 2023 | Nov 2, 2023 · After close | +8.3% |
| Q2 2023 | Aug 14, 2023 · After close | 0.0% |
| Q1 2023 | May 9, 2023 · After close | −0.5% |
| Q4 2022 | Mar 30, 2023 · After close | +2.0% |
| Q3 2022 | Nov 10, 2022 · After close | 0.0% |
| Q2 2022 | Aug 4, 2022 · After close | −1.9% |
| Q1 2022 | May 5, 2022 · After close | −10.1% |
| Q4 2021 | Mar 22, 2022 · After close | −2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Marea Therapeutics — Investor Presentation (November 2026) | Investor deck | 22 slides | November 2026 |
| Merger or Acquisition (September 2026) | Merger or acquisition | 28 slides | Sep 17, 2026 |
| Marea Therapeutics — Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| Investor Presentation (November 2025) | Investor deck | 78 slides | Nov 6, 2025 |
| Investor Presentation (October 2025) | Investor deck | 70 slides | Oct 14, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 71 slides | Aug 7, 2025 |
| Investor Presentation (June 2025) | Investor deck | 70 slides | Jun 26, 2025 |
| Investor Presentation (June 2025) | Investor deck | 65 slides | Jun 17, 2025 |
| Investor Presentation (May 2025) | Investor deck | 56 slides | May 8, 2025 |
| Investor Presentation (February 2025) | Investor deck | 56 slides | Feb 27, 2025 |
Show 50 decks
This page holds 50 of 93 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.0K | 1.00M | 0 | 0 | 0 | 0 | 0 | 0 | 35.3M | |
| Cost of revenue | 146.0K | 174.0K | 189.0K | 69.0K | 55.0K | 63.0K | 65.0K | 225.0K | 372.0K | 31.1M |
| Gross profit | 24.0K | 1.00M | -189.0K | 63.8M | -55.0K | -63.0K | -65.0K | -225.0K | -372.0K | 4.15M |
| Research and development | 7.95M | 11.3M | 12.7M | 13.1M | 17.7M | 9.25M | 10.8M | 7.59M | 15.8M | 16.7M |
| Selling, general and administrative | 10.4M | 12.1M | 13.0M | 14.1M | 11.5M | 9.89M | 9.29M | 9.39M | 11.8M | 12.8M |
| Operating income | -18.2M | -22.4M | -25.7M | -57.6M | -29.1M | -19.1M | -20.1M | -17.0M | -27.6M | -29.5M |
| Depreciation and amortization | 146.0K | 174.0K | 189.0K | 69.0K | 55.0K | 100.0K | 100.0K | 200.0K | 400.0K | 500.0K |
| EBITDA | -18.1M | -22.2M | -25.5M | -57.5M | -29.0M | -19.0M | -20.0M | -16.8M | -27.2M | -29.0M |
| Interest expense | 1.95M | 227.0K | 123.0K | 0 | 5.00K | 378.0K | 1.78M | |||
| Income before tax | -17.5M | -20.8M | -23.2M | -56.7M | -29.0M | -19.0M | -19.4M | -16.2M | -27.7M | -31.3M |
| Income tax | -962.0K | -798.0K | -2.33M | -2.48M | -1.51M | -10.9M | 0 | 0 | -11.5M | 0 |
| Net income | -16.6M | -20.0M | -20.8M | -54.2M | -27.5M | -8.15M | -19.4M | -16.2M | 23.0M | -32.7M |
| Earnings per share, basic | -1.91 | -2.40 | -2.58 | -10.47 | -7.45 | -0.53 | -1.88 | -1.67 | 2.56 | -4.99 |
| Earnings per share, diluted | -1.91 | -2.40 | -2.58 | -10.47 | -7.45 | -0.53 | -1.88 | -1.67 | 2.56 | -4.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.0M | 16.2M | 22.6M | 32.2M | 24.6M | 16.5M | 14.0M | 10.3M | 29.2M | 7.08M |
| Short-term investments | 0 | 15.0M | 27.9M | 37.1M | 70.3M | 18.1M | 11.1M | 32.8M | 25.9M | |
| Receivables | 0 | 900.0K | 0 | 234.5K | 138.8K | |||||
| Inventory | 5.00M | 3.58M | ||||||||
| Current assets | 17.7M | 34.6M | 53.9M | 71.9M | 96.2M | 35.3M | 26.0M | 44.1M | 61.4M | 24.6M |
| Property, plant and equipment | 18.0K | 72.0K | 175.0K | 296.0K | 62.0K | 57.0K | 100.0K | 165.0K | 257.0K | 705.4K |
| Goodwill | 0 | 7.01M | ||||||||
| Total assets | 17.7M | 35.0M | 54.7M | 73.0M | 97.0M | 36.0M | 27.2M | 44.6M | 63.4M | 53.5M |
| Accounts payable | 1.02M | 1.28M | 2.42M | 2.65M | 1.93M | 1.02M | 1.49M | 762.0K | 1.34M | 2.23M |
| Current liabilities | 3.07M | 5.61M | 6.59M | 6.38M | 4.52M | 3.51M | 5.98M | 5.62M | 9.31M | 21.2M |
| Long-term debt | 0 | 2.52M | ||||||||
| Total debt | 137.0K | 168.0K | 485.0K | 714.0K | 624.0K | 978.0K | 0 | 5.65M | ||
| Total liabilities | 3.14M | 5.68M | 6.80M | 6.71M | 5.01M | 3.76M | 6.60M | 7.13M | 13.2M | 30.0M |
| Shareholders' equity | 14.9M | 29.6M | 48.1M | 66.6M | 92.3M | 32.5M | 20.8M | 37.7M | 50.5M | 4.88M |
| Shares outstanding | 8.83M | 8.41M | 8.15M | 7.87M | 3.99M | 19.4M | 10.5M | 9.87M | 9.48M | 8.21M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.9M | -19.4M | -20.0M | -21.2M | -22.2M | -8.82M | -18.9M | -20.0M | -20.9M | -23.7M |
| Capital spending | -28.0K | 0 | 0 | -285.0K | -60.0K | -20.0K | 0 | -134.0K | -135.0K | -1.10M |
| Free cash flow | -16.0M | -19.4M | -20.0M | -21.5M | -22.3M | -8.84M | -18.9M | -20.1M | -21.0M | -24.8M |
| Cash from investing | 15.1M | 13.2M | 10.1M | 28.9M | -54.9M | -7.28M | 21.4M | -4.71M | 41.3M | -2.85M |
| Cash from financing | 599.0K | -206.0K | 385.0K | -224.0K | 85.3M | 18.6M | 1.18M | 824.0K | -932.0K | 20.9M |
| Dividends paid | -15.0M | |||||||||
| Share buybacks | -91 | -267 | -248 | -148 | -130 | -403 | -358 | -72 | ||
| Change in cash | -253.0K | -6.38M | -9.56M | 7.51M | 8.13M | 2.48M | 3.73M | -23.9M | 19.5M | -5.61M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3/A · Registration statement, amended | Nov 19, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Nov 19, 2026 | Current report | SEC |
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| S-3 · Registration statement | Nov 12, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Nov 12, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Oct 19, 2026 | Annual report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Oct 19, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Oct 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Oct 7, 2026 | Meeting notice | SEC |
| D | Oct 2, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 26, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Management or board change | SEC |
| SC TO-T/A | Jul 28, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| SC 14D9/A | Jul 21, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jul 17, 2026 | Material contract | SEC |
| SC 14D9/A | Jul 17, 2026 | Acquisition or disposal | SEC |
| SC TO-T/A | Jul 17, 2026 | Acquisition or disposal | SEC |
| SC 14D9/A | Jul 13, 2026 | Acquisition or disposal | SEC |
| SC TO-T/A | Jul 10, 2026 | Acquisition or disposal | SEC |
| SC 14D9/A | Jul 2, 2026 | Acquisition or disposal | SEC |
| SC 14D9 | Jun 10, 2026 | Acquisition or disposal | SEC |
| SC TO-T | Jun 10, 2026 | Acquisition or disposal | SEC |
| SC14D9C | Jun 9, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Material contract | SEC |
| SC TO-C | Jun 1, 2026 | Other filings | SEC |
| SC14D9C | Jun 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| SC TO-C | May 29, 2026 | Other filings | SEC |
| SC14D9C | May 29, 2026 | Other filings | SEC |
| 8-K · Current report | May 29, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| SC TO-C | May 4, 2026 | Other filings | SEC |
| SC14D9C | May 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 4, 2026 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2026 | Annual report | SEC |
| SC14D9C | Apr 15, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 15, 2026 | Current report | SEC |
| SC14D9C | Apr 2, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| SC14D9C | Mar 9, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| SC14D9C | Feb 27, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 27, 2026 | Current report | SEC |
| SC14D9C | Jan 21, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 21, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 8-K · Current report | Oct 8, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jul 15, 2025 | Current report | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Results | SEC |
| 8-K · Current report | Jun 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 10, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Feb 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Aug 21, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 15, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 10, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | May 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 6, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 1, 2024 | Offer document | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 17, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Mar 28, 2024 | Annual report | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| S-8 · Registration statement for employee plans | Jul 13, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 11, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 14, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| DEFA14A · Additional proxy material | May 1, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| 8-K · Current report | May 1, 2023 | Management or board change | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| 8-K · Current report | Feb 6, 2023 | Results | SEC |
| 4 · Change in ownership | Jan 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| S-8 · Registration statement for employee plans | Oct 17, 2022 | Offer document | SEC |
| 8-K/A · Current report, amended | Oct 14, 2022 | Current report | SEC |
| 8-K/A · Current report, amended | Oct 4, 2022 | Current report | SEC |
| 8-K · Current report | Sep 29, 2022 | Current report | SEC |
| 424B5 · Prospectus | Sep 26, 2022 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2022 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 16, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 15, 2022 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 14, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2022 | Insider trade | SEC |
| 425 | Sep 2, 2022 | Other filings | SEC |
| 8-K · Current report | Aug 19, 2022 | Current report | SEC |
| 425 | Aug 15, 2022 | Other filings | SEC |
| 425 | Aug 10, 2022 | Other filings | SEC |
| 8-K · Current report | Aug 5, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2022 | Quarterly report | SEC |
| 424B3 · Prospectus | Jul 29, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 29, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2022 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 26, 2022 | Offer document | SEC |
| 425 | Jul 6, 2022 | Other filings | SEC |
| S-4 · Registration statement | Jun 15, 2022 | Offer document | SEC |
| 425 | Jun 9, 2022 | Other filings | SEC |
| 8-K · Current report | May 23, 2022 | Current report | SEC |
| 10-Q · Quarterly report | May 5, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2022 | Results | SEC |
| 425 | Apr 27, 2022 | Other filings | SEC |
| 8-K · Current report | Apr 27, 2022 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 21, 2022 | Annual report | SEC |
| 10-K · Annual report | Mar 22, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 22, 2022 | Results | SEC |
| 8-K · Current report | Feb 25, 2022 | Management or board change | SEC |
| 8-K · Current report | Feb 18, 2022 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 3, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 19, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2022 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Lisata Therapeutics, Inc.’s releases
- Common shares
- 10,804,066
- Fully diluted
- 10,804,066
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 10,804,066 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 10,804,066 |
| Nov 19, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Since at least Sep 17, 2026 |
| Richard J. Berman Other companies: COMSovereign Holding Corp. (Director · Since at least Jan 21, 2021); Celularity Inc. (Director · Aug 27, 2024 – Dec 19, 2024 · Past); Sidus Space, Inc. (Director · Jan 18, 2024 – Jan 18, 2024 · Past); Context Therapeutics Inc. (Director · Oct 19, 2021 – Jun 13, 2024 · Past); BioVie Inc. (Director · Sep 28, 2021 – Nov 20, 2024 · Past); Frontier Investment Corp (Director · Jun 30, 2021 – Jun 30, 2021 · Past); TraqIQ Inc (Director · Apr 5, 2021 – Apr 5, 2021 · Past); Cuentas Inc. (Director · Sep 13, 2018 – Dec 20, 2018 · Past); Catasys Inc (Director · Mar 11, 2017 – Aug 2, 2018 · Past); CryoPort, Inc. (Director · Jan 12, 2015 – May 17, 2024 · Past); MetaStat Inc (Director · Oct 15, 2014 – Mar 27, 2015 · Past); Dyadic International, Inc. (Director · Feb 10, 2006 – Jan 2, 2007 · Past); Easylink Services International Corp (Director · Jan 5, 2006 – Jul 2, 2012 · Past); Advaxis Inc (Director · Dec 31, 2005 – May 4, 2020 · Past) | Director · Nov 15, 2006 – Jan 9, 2017 · Past |
| Anne C. Whitaker Other companies: Alkermes plc (Director · Since at least Sep 14, 2026); ICON plc (Director · Since at least Mar 18, 2026); OraSure Technologies, Inc. (Director · Nov 8, 2021 – May 15, 2023 · Past); Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Bausch Health Companies Inc. (EVP, Company Group Chairman · May 13, 2015 – Dec 5, 2016 · Past); Madrigal Pharmaceuticals, Inc. (President and CEO, Director · Mar 2, 2014 – Sep 3, 2014 · Past); Wolfspeed, Inc. (Director · Dec 2, 2013 – Nov 5, 2020 · Past) | Director · Nov 1, 2020 – Jan 10, 2022 · Past |
| Jeffrey Farrow Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 29, 2026); Tarsus Pharmaceuticals, Inc. (See Remarks · Since at least Apr 24, 2023); Global Blood Therapeutics Inc (Chief Financial Officer · Apr 4, 2016 – Oct 5, 2022 · Past); ZS Pharma Inc (Chief Financial Officer · Jul 8, 2015 – Dec 17, 2015 · Past); Hyperion Therapeutics Inc (CFO · Jul 25, 2012 – May 7, 2015 · Past); Renovis Inc (V.P., Finance and CAO · Jul 1, 2007 – May 2, 2008 · Past) | Director · Since Oct 13, 2026 · Appointed, no departure found |
| Michael Davidson Other companies: BioAge Labs, Inc. (Independent Director · Since at least Mar 26, 2024); NewAmsterdam Pharma Company N.V. (Chief Executive Officer · Since at least Dec 29, 2023); Tenax Therapeutics, Inc. (Board Director · Since at least Feb 25, 2021); Silence Therapeutics PLC (Director · Jan 2, 2025 – Jan 2, 2025 · Past); Omthera Pharmaceuticals Inc (Executive VP & CMO · Apr 11, 2013 – Jul 18, 2013 · Past) | Director · Jul 28, 2020 – Jan 10, 2022 · Past |
| David J. Mazzo Other companies: Palisade Bio, Inc. (Director · Jun 17, 2019 – Apr 1, 2021 · Past); Tobira Therapeutics Inc (Chief Executive Officer, Director · Aug 21, 2013 – Jan 1, 2014 · Past); EyePoint, Inc. (Director · Jul 13, 2007 – Feb 28, 2020 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – Feb 12, 2014 · Past) | President and Chief Executive Officer · Since at least Jan 5, 2015 |
| Heidi Henson Other companies: Perspective Therapeutics, Inc. (Director · Since at least Jun 1, 2023); PepGen Inc. (Non-Executive Director · Since at least May 5, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past) | Director · Since at least Sep 15, 2022 |
| Robert Dickey IV Other companies: Vyome Holdings, Inc. (Chief Financial Officer · Since at least Aug 15, 2025); Enveric Biosciences, Inc. (Chief Financial Officer · Sep 9, 2022 – Sep 9, 2022 · Past); Emmaus Life Sciences, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); AIM ImmunoTech Inc. (Chief Financial Officer · Jun 11, 2009 – Apr 4, 2022 · Past) | Chief Financial Officer · Aug 19, 2013 – Dec 31, 2014 · Past |
| Alan G Harris Other companies: Radius Health, Inc. (Chief Medical Officer · Feb 21, 2014 – Dec 17, 2014 · Past); NPS Pharmaceuticals Inc (SVP, Chief Medical Officer · Jan 2, 2008 – Jan 2, 2008 · Past); TG Therapeutics, Inc. (Chief Medical Officer · Feb 1, 2006 – Apr 25, 2007 · Past) | See Remarks · Jul 6, 2009 – Apr 4, 2011 · Past |
| Gregory B. Brown Other companies: Aquestive Therapeutics, Inc. (Chair of the Board, Aquestive Director and Co-founder of HealthCare Royalty Partners · Since at least Jul 24, 2018); Cambrex Corporation (Director · Oct 31, 2017 – Dec 4, 2019 · Past); Invuity Inc (Director · Jun 11, 2015 – Jun 11, 2015 · Past) | Director · Since at least Oct 10, 2016 |
All 36 people
| Person | Seat |
|---|---|
| Joshua Lehrer-Graiwer Other companies: Fulcrum Therapeutics, Inc. (Director · Since at least Apr 23, 2026); LENZ Therapeutics, Inc. (PRESIDENT AND CEO, Director · Jan 13, 2021 – Feb 21, 2023 · Past); Global Blood Therapeutics Inc (Chief Medical Officer · Oct 1, 2019 – Mar 5, 2020 · Past) | President & COO · Since at least Sep 17, 2026 |
| Mohammad Azab Other companies: Durect Corporation (Director · Since at least Jan 4, 2021); Xenon Pharmaceuticals Inc. (Director · Nov 4, 2014 – Dec 19, 2023 · Past); Astex Pharmaceuticals Inc (Chief Medical Officer · Jul 21, 2009 – Oct 11, 2013 · Past) | Director · Since at least Sep 15, 2022 |
| Peter Traber Other companies: Cartesian Therapeutics, Inc. (Head of Research and Development · Since at least Aug 1, 2020); Galectin Therapeutics Inc. (President & CEO · Feb 12, 2009 – Jun 13, 2018 · Past); Tanox Inc (Director · Jun 2, 2006 – Jun 2, 2006 · Past) | Director · Jan 22, 2015 – Jan 10, 2022 · Past |
| Steven M Klosk Other companies: Bolt Projects Holdings, Inc. (Director · Aug 13, 2024 – Nov 25, 2024 · Past); Golden Arrow Merger Corp (Director · Mar 16, 2021 – Mar 16, 2021 · Past); Cambrex Corporation (President & CEO, Director · May 3, 2016 – Dec 4, 2019 · Past) | Director · Since at least Jun 22, 2016 |
| Cynthia L. Flowers Other companies: Kadmon Holdings Inc (Director · Jan 22, 2019 – Nov 8, 2021 · Past); G1 Therapeutics Inc (Director · Jun 7, 2018 – Sep 18, 2024 · Past) | Director · Since at least Nov 7, 2018 |
| Douglas W Losordo Other companies: Cadrenal Therapeutics, Inc. (Chief Medical Officer · Jan 19, 2023 – Jan 18, 2024 · Past); Longeveron Inc. (Director · Feb 11, 2021 – Dec 21, 2023 · Past) | See Remarks · Aug 5, 2013 – Jan 13, 2020 · Past |
| Todd C. Girolamo Other companies: ProKidney Corp. (Chief Legal Officer and Secretary · Since at least Jul 11, 2022); Longeveron Inc. (Director · Feb 15, 2022 – Dec 21, 2022 · Past) | CLO, SVP of Corp Dev · Jun 17, 2021 – Jan 13, 2022 · Past |
| Catherine M Vaczy Other companies: Genprex, Inc. (EVP GC Chief Strategy Officer · Mar 12, 2020 – Apr 21, 2023 · Past) | General Counsel · Oct 31, 2008 – Apr 13, 2015 · Past |
| Jeff Farrow Other companies: Tarsus Pharmaceuticals, Inc. (Chief Financial Officer and Chief Strategy Officer · Since at least Nov 4, 2026) | Director · Since at least Oct 14, 2026 |
| Joseph Talamo Other companies: Intensity Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 11, 2023) | SVP and CFO · Jan 8, 2018 – Jan 13, 2020 · Past |
| Martin E Schmieg Other companies: Fibrocell Science Inc (CFO, Sr. VP · Dec 31, 2005 – Dec 31, 2005 · Past) | Vice President- Corporate Dev · Jun 25, 2012 – Jun 25, 2012 · Past |
| Robert S Vaters Other companies: Orthofix Medical Inc. (President and CEO · Sep 7, 2008 – Feb 27, 2013 · Past) | President & CFO, Director · Jan 5, 2015 – Aug 12, 2015 · Past |
| Steven S Myers Other companies: QuantumSphere Inc (Director · Aug 19, 2014 – May 18, 2015 · Past) | Director · Nov 16, 2006 – Jan 10, 2022 · Past |
| Ian Zhang | See Remarks · Sep 1, 2010 – Apr 4, 2011 · Past |
| James Nisco | Senior Vice President, Finance and Treasury and Chief Accounting Officer · Since at least Apr 15, 2024 |
| Jason Kolbert | See Remarks · Mar 4, 2011 – Jan 4, 2012 · Past |
| Jian M Zhang | See Remarks · Oct 30, 2009 – Jun 9, 2010 · Past |
| John Menditto | Vice President, Investor Relations and Corporate Communications · Since at least Aug 4, 2026 |
| Joseph Zuckerman | Director · Aug 30, 2006 – May 21, 2009 · Past |
| Kristen K Buck | EVP, R&D and CMO · Since at least Sep 1, 2021 |
| Mingsheng Shi | See Remarks, Director · Jun 1, 2010 – Jan 4, 2012 · Past |
| Renee Cohen | VP of Oper. & Corp. Strategy · Aug 15, 2007 – Feb 27, 2008 · Past |
| Robert A Preti | See Remarks, Director · Jan 19, 2011 – Apr 25, 2017 · Past |
| Robert Dillman | See Remarks · May 8, 2014 – May 9, 2014 · Past |
| Steven M. Klosk | Director · Since at least Nov 4, 2026 |
| Tariq Imam | Senior Vice President, Business Development and Operations and General Counsel · Since at least Feb 3, 2025 |
Log in to ask 6ix AI your own questions about Lisata Therapeutics, Inc.